Company: ABUS
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001447028-25-000115
Chunk: 20

Company: Arbutus Biopharma Corp
Filing Date: 2025-08-06
Form: 10-Q
Item: Part I, Item 1
Chunk 20
---
 21,765 Issuance of common shares pursuant to exercise of options1,126,691 4,268 (1,814)— — 2,454 Issuance of common shares pursuant to ESPP121,563 271 (60)— — 211 Issuance of common shares upon vesting of RSUs410,482 1,190 (1,190)— — — Unrealized gain on available-for-sale securities— — — — 50 50 Net loss— — — (17,875)— (17,875)Balance March 31, 2024180,192,227 $1,377,315 $80,220 $(1,294,527)$(48,371)$114,637 Stock-based compensation expense— — 3,180 — — 3,180 Issuance of common shares pursuant to the Open Market Sale Agreement7,833,922 22,359 — — — 22,359 Issuance of common shares pursuant to exercise of options712,895 3,660 (1,649)— — 2,011 Unrealized gain on available-for-sale securities— — — — 63 63 Net loss— — — (19,796)— (19,796)Balance June 30, 2024188,739,044 $1,403,334 $81,751 $(1,314,323)$(48,308)$122,454 

See accompanying notes to the condensed consolidated financial statements.

4

ARBUTUS BIOPHARMA CORPORATION

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(In thousands of U.S. Dollars)

 Six Months Ended June 30, 20252024OPERATING ACTIVITIESNet loss$(22,003)$(37,671)Non-cash items:Depreciation341 711 Loss on impairment of leasehold improvements and lab equipment2,811 — Stock-based compensation expense4,428 5,194 Change in fair value of contingent consideration559 391 Non-cash royalty revenue(974)(1,164)Non-cash interest expense55 70 Net accretion and amortization of investments in marketable securities(1,386)(1,229)Net change in operating